Step 1: The sentiment in the management's discussion appears to be cautiously optimistic. The company emphasizes its mission to deliver innovative medicines and its strategy to combine pharmaceutical resources with biotech's focus on innovation. They highlight the completion of significant acquisitions like Celgene and MyoKardia, positioning themselves as a leading biopharmaceutical company. However, they also acknowledge the challenges posed by the COVID-19 pandemic and its potential negative impact on their business.

Step 2: 
- Revenue Growth: The company mentions a substantial revenue increase of 73% for the nine months ended September 30, 2020, mainly attributed to the Celgene acquisition, demonstrating significant growth in their operations.
- Impact of COVID-19: While the pandemic has not significantly impacted the company's results of operations, they recognize the uncertainty surrounding its potential future effects on their business, financial condition, and operations.
- Financial Measures: The company provides non-GAAP financial measures adjusted to exclude certain costs and expenses, reflecting transparency in financial reporting and a focus on profitability and efficiency.

Step 3: Despite the challenges posed by the COVID-19 pandemic, the company has managed to achieve significant revenue growth, especially through acquisitions like Celgene. They have demonstrated resilience by adapting to the changing healthcare landscape and ensuring the safety and productivity of their workforce. The proactive measures taken to protect employee health and ensure business continuity indicate a strong operational response.

Step 4: Low risk of bankruptcy. The company's robust revenue growth, successful acquisitions, and adaptability to the challenges posed by the COVID-19 pandemic indicate a stable financial position. The cautious optimism in their approach, coupled with effective financial measures and operational strategies, suggest that the company is well-positioned to sustain its operations and navigate through uncertainties, reducing the risk of bankruptcy.